Liminal BioSciences, Inc.
(NASDAQ : LMNL)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -0.08%132.190.0%$1230.60m
OCGNOcugen, Inc. -2.56%8.740.0%$941.39m
NVAXNovavax, Inc. 10.59%174.8492.9%$613.91m
REGNRegeneron Pharmaceuticals, Inc. 2.71%461.572.7%$556.12m
AMGNAmgen, Inc. 2.62%227.731.3%$540.12m
GILDGilead Sciences, Inc. 2.20%64.621.0%$516.91m
ILMNIllumina, Inc. -0.19%398.853.5%$484.87m
VRTXVertex Pharmaceuticals, Inc. 2.02%211.981.9%$458.30m
ALXNAlexion Pharmaceuticals, Inc. 1.11%150.102.0%$339.49m
BIIBBiogen, Inc. 2.71%270.711.7%$305.38m
CRSPCRISPR Therapeutics AG -0.73%114.650.6%$304.78m
BNGOBioNano Genomics, Inc. 3.62%7.150.0%$275.81m
EXASEXACT Sciences Corp. 0.51%121.6418.4%$251.13m
SGENSeagen Inc. 2.68%149.355.8%$225.25m
PACBPacific Biosciences of California, Inc. 1.70%29.277.2%$176.23m

Company Profile

Liminal BioSciences, Inc. is a biopharmaceutical corporation. The firm engages in the development of therapeutic products focusing on unmet medical needs in the field of fibrosis, autoimmune disease or inflammation and cancer. It operates through the following segments: Small Molecule Therapeutics and Plasma-derived Therapeutics. The Small Molecule Therapeutics segment focuses on discovering, developing and commercializing novel treatments for patients suffering from diseases related to fibrosis, including conditions of the lung, liver and kidney. The Plasma-derived Therapeutics segment provides efficient extraction and purification of therapeutic proteins from human plasma. The company was founded on October 14, 1994 and is headquartered in Laval, Canada.